LongevityFDA Approved

Gonadotropin Releasing Hormone (GnRH) Agonists

Overview

Gonadotropin-releasing hormone agonists are synthetic decapeptide analogues of native GnRH that initially stimulate and then suppress gonadotropin secretion from the pituitary gland. Following initial receptor activation, continuous GnRH agonist exposure leads to receptor downregulation and reversible suppression of the hypothalamic-pituitary-gonadal axis, reducing sex steroid production. Approved formulations include leuprolide, goserelin, and triptorelin, used primarily in hormone-sensitive cancers and reproductive medicine. The longevity rationale derives from theoretical models linking reduced reproductive signaling to extended lifespan observed in model organisms, though this remains speculative in humans.

Key Research Findings

GnRH agonists are FDA approved for prostate cancer, endometriosis, uterine fibroids, and central precocious puberty, with extensive clinical trial data supporting efficacy in these indications. Evidence connecting GnRH suppression to human longevity is indirect and based primarily on observational data and evolutionary biology hypotheses rather than prospective longevity trials. Long-term GnRH agonist therapy is associated with bone mineral density loss and metabolic changes that may offset theoretical longevity benefits.

Route of Administration

Subcutaneous injection, Intramuscular injection, Subcutaneous implant, Intranasal

Regulatory Status

FDA Approved

Interested in Gonadotropin Releasing Hormone (GnRH) Agonists?

Find a verified provider experienced with Gonadotropin Releasing Hormone (GnRH) Agonists protocols in your area. All providers are credentialed and use compliant sourcing.

Find a Gonadotropin Releasing Hormone (GnRH) Agonists Provider

Related Peptides

Epithalon (Epitalon)

Research Phase

A synthetic tetrapeptide (Ala-Glu-Asp-Gly) based on the natural epithalamin peptide produced by the pineal gland. Epithalon activates telomerase, the enzyme responsible for maintaining telomere length, thereby potentially extending cellular replicative capacity. It also stimulates melatonin production and modulates neuroendocrine system function associated with aging.

MOTS-c

Research Phase

A mitochondrial-derived peptide encoded by the 12S rRNA gene of mitochondrial DNA. MOTS-c is a 16-amino acid peptide that acts as an exercise mimetic by activating AMPK and regulating metabolic homeostasis. It translocates to the nucleus under metabolic stress to regulate nuclear gene expression related to glucose metabolism and cellular stress responses.

Humanin

Research Phase

A 24-amino acid mitochondrial-derived peptide encoded within the 16S rRNA region of mitochondrial DNA. Humanin exerts cytoprotective and neuroprotective effects by interacting with IGFBP-3, BAX, and the FPRL-1 receptor. It inhibits apoptosis through suppression of the intrinsic mitochondrial death pathway and reduces amyloid-beta-induced neurotoxicity.

NAD+ Precursors (NMN)

In Clinical Trials

Nicotinamide mononucleotide (NMN) is a direct biosynthetic precursor to nicotinamide adenine dinucleotide (NAD+), a coenzyme essential for cellular metabolism, DNA repair (via sirtuins and PARPs), and circadian rhythm regulation. NAD+ levels decline with age, and NMN supplementation restores tissue NAD+ levels, activating SIRT1-mediated pathways that regulate mitochondrial biogenesis and oxidative stress resistance.